In general , stimulants improved driving performance in ADHD patients ( either in RCTs conducted in simulators and /or cars ) .
MPH-OROS  improved driving performance compared with MAS-XR , placebo , or no-drug conditions .
Although MPH-OROS and MPH-IR produced similar improvements during the day , MPH-IR lost its efficacy in the evening .
MAS-XR also improved driving performance , but worsened driving performance in the evening .
Studies with ATX report conflicting results .
Improvement was more consistent in teenagers and young adults .
In general , treatment with psychostimulants or ATX in therapeutic dosages had no negative impact on driving performance of ADHD patients .
To conclude , treatment with stimulants in therapeutic doses improves driving performance in ADHD patients , especially teenagers and young adults
Adults with Attention Deficit Hyperactivity Disorder ( ADHD ) , especially teenagers and young adults , show important car driving impairments , including risky driving , accidents , fines and suspension of driver׳s license .
We systematic ally review ed the efficacy of stimulant and non-stimulant drugs on driving performance of ADHD patients .
Event-related potentials in adults with Attention-Deficit/Hyperactivity Disorder: an investigation using an inter-modal auditory/visual oddball task.
This study investigated whether ERPs from an inter-modal oddball task could distinguish between adults with Attention-Deficit/Hyperactivity Disorder ( AD/HD ) and controls . Two age-matched groups of young adult males ( 18 AD/HD , 18 controls ) were presented with an inter-modal oddball task in which a counter-phasing checkerboard was the non-target visual stimulus ( r and omly presented on 80 % of trials ) , and a 2000 Hz tone was the auditory target ( 20 % of trials ) . Stimuli were presented at a fixed rate ( stimulus-onset asynchrony 1.03 s ) and participants were required to silently count all targets . The AD/HD group showed globally enhanced P2 and reduced N2 amplitudes to auditory targets , with no differences in target P3 , together with topographic differences in N1 to auditory targets , and P1 , N1 , P2 , N2 and P3 to visual non-targets , compared with controls . These results were interpreted in terms of early sensory-processing impairments in adults with AD/HD , which may be partially overcome through effortful processing , as reflected in the later endogenous ERP components
In general , stimulants improved driving performance in ADHD patients ( either in RCTs conducted in simulators and /or cars ) .
MPH-OROS  improved driving performance compared with MAS-XR , placebo , or no-drug conditions .
Although MPH-OROS and MPH-IR produced similar improvements during the day , MPH-IR lost its efficacy in the evening .
MAS-XR also improved driving performance , but worsened driving performance in the evening .
Studies with ATX report conflicting results .
Improvement was more consistent in teenagers and young adults .
In general , treatment with psychostimulants or ATX in therapeutic dosages had no negative impact on driving performance of ADHD patients .
To conclude , treatment with stimulants in therapeutic doses improves driving performance in ADHD patients , especially teenagers and young adults
Adults with Attention Deficit Hyperactivity Disorder ( ADHD ) , especially teenagers and young adults , show important car driving impairments , including risky driving , accidents , fines and suspension of driver׳s license .
We systematic ally review ed the efficacy of stimulant and non-stimulant drugs on driving performance of ADHD patients .